CO2017007940A2 - Péptidos antagonistas prgc - Google Patents

Péptidos antagonistas prgc

Info

Publication number
CO2017007940A2
CO2017007940A2 CONC2017/0007940A CO2017007940A CO2017007940A2 CO 2017007940 A2 CO2017007940 A2 CO 2017007940A2 CO 2017007940 A CO2017007940 A CO 2017007940A CO 2017007940 A2 CO2017007940 A2 CO 2017007940A2
Authority
CO
Colombia
Prior art keywords
prgc
antagonist peptides
compounds
formula
antagonist
Prior art date
Application number
CONC2017/0007940A
Other languages
English (en)
Inventor
Kazimierz Wisniewski
Guangcheng Jiang
K Aleksandr Rabinovich
J Javier Sueiras-Diaz
Original Assignee
Ferring Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ferring Bv filed Critical Ferring Bv
Publication of CO2017007940A2 publication Critical patent/CO2017007940A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64—Cyclic peptides containing only normal peptide links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pyridine Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Esta revelación se relaciona con compuestos de la fórmula o una sal farmacéuticamente aceptable de los mismos: en los cuales m, p, A, Ar’, Ar2, Ar3, R’, R2, y R3 se definen en la especificación. Los compuestos de la fórmula (1) podrán usarse como antagonistas PRGC y podrán usarse para tratar la migraña.
CONC2017/0007940A 2015-01-06 2017-08-04 Péptidos antagonistas prgc CO2017007940A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562100371P 2015-01-06 2015-01-06
PCT/EP2016/050110 WO2016110499A1 (en) 2015-01-06 2016-01-06 Cgrp antagonist peptides

Publications (1)

Publication Number Publication Date
CO2017007940A2 true CO2017007940A2 (es) 2017-10-31

Family

ID=55071041

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2017/0007940A CO2017007940A2 (es) 2015-01-06 2017-08-04 Péptidos antagonistas prgc

Country Status (34)

Country Link
US (1) US9969775B2 (es)
EP (1) EP3242882B1 (es)
JP (1) JP6929227B2 (es)
KR (1) KR20170102302A (es)
CN (1) CN107207567B (es)
AR (1) AR103499A1 (es)
AU (1) AU2016206059B2 (es)
BR (1) BR112017013413A2 (es)
CA (1) CA2973041A1 (es)
CL (1) CL2017001761A1 (es)
CO (1) CO2017007940A2 (es)
DK (1) DK3242882T3 (es)
EA (1) EA032082B1 (es)
ES (1) ES2924410T3 (es)
HR (1) HRP20220941T1 (es)
HU (1) HUE059379T2 (es)
IL (1) IL252903B (es)
JO (1) JO3669B1 (es)
LT (1) LT3242882T (es)
MA (1) MA41311B1 (es)
MD (1) MD3242882T2 (es)
MX (1) MX2017008893A (es)
MY (1) MY196439A (es)
PH (1) PH12017501214A1 (es)
PL (1) PL3242882T3 (es)
PT (1) PT3242882T (es)
RS (1) RS63467B1 (es)
SA (1) SA517381865B1 (es)
SG (1) SG11201705306UA (es)
SI (1) SI3242882T1 (es)
TN (1) TN2017000248A1 (es)
TW (1) TWI717331B (es)
UA (1) UA121490C2 (es)
WO (1) WO2016110499A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111479823A (zh) * 2017-11-06 2020-07-31 奥克兰联合服务有限公司 肽缀合物cgrp受体拮抗剂及其制备方法和用途

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6268474B1 (en) * 1998-04-30 2001-07-31 Creighton University Peptide antagonists of CGRP-receptor superfamily and methods of use
TW200533398A (en) 2004-03-29 2005-10-16 Bristol Myers Squibb Co Novel therapeutic agents for the treatment of migraine
US20060004185A1 (en) * 2004-07-01 2006-01-05 Leese Richard A Peptide antibiotics and peptide intermediates for their prepartion
US7659264B2 (en) * 2004-10-07 2010-02-09 Merck Sharp & Dohme Corp. CGRP receptor antagonists
BRPI0606647A2 (pt) * 2005-01-17 2009-07-14 Jerini Ag antagonistas do receptor de c5a
CN101208303A (zh) * 2005-03-14 2008-06-25 默克公司 Cgrp受体拮抗剂
US8168592B2 (en) * 2005-10-21 2012-05-01 Amgen Inc. CGRP peptide antagonists and conjugates
EP3842458A1 (en) * 2005-11-14 2021-06-30 Teva Pharmaceuticals International GmbH Antagonist antibodies directed against calcitonin gene-related peptide
MX2008015906A (es) * 2006-06-13 2009-03-06 Vertex Pharma Antagonistas del receptor del peptido relacionado con el gen de calcitonina.
EP2807187B1 (en) 2012-01-26 2017-07-26 Christopher J. Soares Peptide antagonists of the calcitonin cgrp family of peptide hormones and their use

Also Published As

Publication number Publication date
JP2018505213A (ja) 2018-02-22
JO3669B1 (ar) 2020-08-27
SA517381865B1 (ar) 2021-09-15
HRP20220941T1 (hr) 2022-10-28
JP6929227B2 (ja) 2021-09-01
AU2016206059B2 (en) 2019-07-25
TN2017000248A1 (en) 2018-10-19
MA41311A (fr) 2017-11-14
MX2017008893A (es) 2017-10-25
US9969775B2 (en) 2018-05-15
DK3242882T3 (en) 2022-08-08
IL252903A0 (en) 2017-08-31
PT3242882T (pt) 2022-08-09
BR112017013413A2 (pt) 2018-01-09
CN107207567B (zh) 2021-11-23
TWI717331B (zh) 2021-02-01
EP3242882B1 (en) 2022-05-04
WO2016110499A1 (en) 2016-07-14
TW201630929A (zh) 2016-09-01
CL2017001761A1 (es) 2018-01-26
SG11201705306UA (en) 2017-07-28
AR103499A1 (es) 2017-05-17
EA201791456A1 (ru) 2018-01-31
MD3242882T2 (ro) 2022-10-31
LT3242882T (lt) 2022-08-25
MA41311B1 (fr) 2022-10-31
US20180002378A1 (en) 2018-01-04
SI3242882T1 (sl) 2022-09-30
UA121490C2 (uk) 2020-06-10
HUE059379T2 (hu) 2022-11-28
CA2973041A1 (en) 2016-07-14
PH12017501214A1 (en) 2018-01-08
PL3242882T3 (pl) 2022-10-31
IL252903B (en) 2021-01-31
KR20170102302A (ko) 2017-09-08
RS63467B1 (sr) 2022-08-31
MY196439A (en) 2023-04-11
CN107207567A (zh) 2017-09-26
EP3242882A1 (en) 2017-11-15
AU2016206059A1 (en) 2017-07-20
ES2924410T3 (es) 2022-10-06
EA032082B1 (ru) 2019-04-30

Similar Documents

Publication Publication Date Title
CL2018003290A1 (es) Amidas heterocíclicas útiles como moduladores de proteínas (divisional de solicitud cl 2850-2018).
CY1121413T1 (el) Διυδροπυρρολοπυριδινης αναστολεις ror-γαμμα
NI201700020A (es) Compuestos de aminopirimidinilo como inhibidores de jak
ECSP20025899A (es) Compuestos útiles para inhibir a cdk7
EA201792536A1 (ru) Триазоловые агонисты рецептора apj
EA201891024A1 (ru) Соединения-ингибиторы tank-связывающей киназы
EA201692249A1 (ru) Ингибиторы фосфатидилинозитол-3-киназы
EA201790078A1 (ru) Ингибиторы mnk и связанные с ними способы
EA201692203A1 (ru) Соединения, ингибирующие tank-связывающую киназу
EA201591420A1 (ru) Гетероарильные соединения и их применение
AR103680A1 (es) Inhibidores selectivos de bace1
EA201790395A1 (ru) Производные аминотриазина, подходящие для применения в качестве соединений-ингибиторов tank-связывающей киназы
UY35684A (es) Formulación de inhibidores de la tirosina quinasa de bazo (syk)
EA201692266A1 (ru) Ингибиторы фосфатидилинозитол-3-киназы
EA201692268A1 (ru) Ингибиторы фосфатидилинозитол-3-киназы
EA201692267A1 (ru) Ингибиторы фосфатидилинозитол-3-киназы
EA201692265A1 (ru) Ингибиторы фосфатидилинозитол-3-киназы
BR112015020139A2 (pt) compostos terapêuticos e usos dos mesmos
CL2015002897A1 (es) Inhibidores de bace1
EA201790627A1 (ru) СТИМУЛЯТОРЫ рГЦ
EA201791289A1 (ru) Ингибиторы клеточного некроза и связанные с ними способы
EA201692470A1 (ru) Фармацевтические комбинации
EA201692474A1 (ru) Производные 1-(циклопент-2-ен-1-ил)-3-(2-гидрокси-3-(арилсульфонил)фенил)мочевины в качестве ингибиторов cxcr2
EA201692289A1 (ru) Замещенные [1,2,4]триазольные и имидазольные соединения в качестве фунгицидов
CU24434B1 (es) Compuestos derivados de n-(1,5-dimetil-3-oxo-2,3-dihidro-1h-pirazol-4-il)-4-metil-5-isoxazol-3-carboxamida activos como inhibidores selectivos de smurf-1